Business
Kintara Therapeutics Announces Three Abstracts Have Been Accepted for the 2022 Society for Neuro-Oncology Annual Meeting
SAN DIEGO, Sept. 8, 2022 /PRNewswire/ -- Kintara Therapeutics, Inc.(Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the
About this update from Tuhura Biosciences, Inc.
[{"type":"text","content":"SAN DIEGO, Sept. 8, 2022 /PRNewswire/ -- Kintara Therapeutics, Inc.(Nasdaq: KTRA) (\"Kintara\" or the \"Company\"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced that three posters have been accepted for data presentation at the 2022 Society for Neuro-Oncology (SNO) Annual Meeting. The 2022 SNO Annual Meeting will be held from November 16 through November 20, 2022 in Tampa, Florida.\nData Presentations:\nPhase 2 Study of VAL-083 and Radiotherapy in Newly-Diagnosed, MGMT-unmethylated GBMPoster Presenter: Zhongping Chen, MD, Ph.D. – Sun Yat-sen University Cancer Center(Presentation Time: Friday, November 18, 2022 - 7:30 to 9:30 pm ET)\nRecurrent RELA Fusion-Positive Ependymoma Treated with VAL-083 under Expanded Access: A Case ReportPoster Presenter: Carlos Kamiya-Matsuoka, MD – MD Anderson Cancer Center(Presentation Time: Friday, November 18, 2022 - 7:30 to 9:30 pm ET)\nVAL-083 in Patients with Recurrent Glioblastoma Treated under Expanded Access ProgramPoster Presenter: Carlos Kamiya-Matsuoka, MD – MD Anderson Cancer Center(Presentation Time: Friday, November 18, 2022 - 7:30 to 9:30 pm ET) \nABOUT KINTARALocated in San Diego, California, Kintara is dedicated to the development of novel cancer therapies for patients with unmet medical needs. Kintara is developing two late-stage, Phase 3-ready therapeutics for clear unmet medical needs with reduced risk development programs. The two programs are VAL-083 for Glioblastoma Multiforme (GBM) and REM-001 for Cutaneous Metastatic Breast Cancer (CMBC).\nVAL-083 is a \"first-in-class,\" small-molecule chemotherapeutic with a novel mechanism of action that has demonstrated clinical activity against a range of cancers, including central nervous system, ovarian and other solid tumors (e.g., NSCLC, bladder cancer, head and neck) in U.S. clinical trials sponsored by the National Cancer Institute (NCI). Based on Kintara's internal research programs and these prior NCI-sponsored clinical studies, Kintara is currently advancing VAL-083 in the GBM AGILE study to support the development and commercialization of VAL-083 in GBM.\nKintara is also advancing its proprietary, late-stage photodynamic therapy platform that holds promise as a localized cutaneous, or visceral, tumor treatment as well as in other potential indications. REM-001 thera...